KB-1588

SAR441344-hIgG1

×
Please enable JavaScript in your browser to complete this form.
45958
Home » Antibodies » SAR441344-hIgG1

Background of SAR441344-hIgG1

The CD40 receptor and CD40L ligand are transmembrane proteins that are part of the tumor necrosis factor (TNF) receptor superfamily and are imperative to the induction and maintenance of inflammation. Frexalimab, a monoclonal antibody targeting the CD40-CD40L pathway, shows promise in treating various autoimmune diseases by reducing inflammation and tissue damage.

Specifications

Catalog NumberKB-1588
Antibody NameSAR441344-hIgG1
IsotypeHuman IgG1,kappa
FC MuationsWild Type
TargetCD40L
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Fatima T, Mirza A, Fatima F, Karamat RI, Ahmad B, Naeem S, Shahid I, Akilimali A. Frexalimab (SAR441344) as a potential multiautoimmune disorder tackling mAB targeting the CD40-CD40L pathway undergoing clinical trials: a review. Ann Med Surg (Lond). 2024 Nov 12;86(12):7305-7313.
Please enable JavaScript in your browser to complete this form.